Back to Search
Start Over
Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia
- Source :
- The Journal of antimicrobial chemotherapy. 73(2)
- Publication Year :
- 2017
-
Abstract
- Background Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation. Methods Patients with HIV suppressed viraemia (plasma viral load
- Subjects :
- 0301 basic medicine
Microbiology (medical)
Male
medicine.medical_specialty
Sustained Virologic Response
Anti-HIV Agents
030106 microbiology
Human immunodeficiency virus (HIV)
HIV Infections
Drug resistance
medicine.disease_cause
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Internal medicine
Drug Resistance, Viral
medicine
Humans
Pharmacology (medical)
030212 general & internal medicine
Dose Reduced
Darunavir
Pharmacology
Ritonavir
business.industry
virus diseases
Lopinavir
Middle Aged
Viral Load
Atazanavir
Infectious Diseases
Treatment Outcome
HIV-1
Female
business
Viral load
medicine.drug
Subjects
Details
- ISSN :
- 14602091
- Volume :
- 73
- Issue :
- 2
- Database :
- OpenAIRE
- Journal :
- The Journal of antimicrobial chemotherapy
- Accession number :
- edsair.doi.dedup.....e568e8125602e9a26935fca0e1be5a3c